Stemline Therapeutics, Inc. (NasdaqCM:STML) will look for acquisitions. Stemline Therapeutics announced that it intends to offer and sell, subject to market conditions, 5,000,000 shares of its common stock in an underwritten public offering. In addition, Stemline intends to grant the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock offered in the public offering. Stemline intends to use the net proceeds from the offering for commercial activities of ELZONRIS (tagraxofusp; SL-401), clinical trials for additional indications including CMML, MF, AML, and potentially other diseases such as certain lymphomas, clinical development of additional pipeline candidates (felezonexor (SL-801), SL-1001, SL-901 and SL-701), research and development and regulatory activities, potential acquisitions and in-licensing; and (v) other general corporate purposes.